Drug Trial Radar · NCT05203510
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
Last checked: Nov 20, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
52
Actual
Start
Oct 20, 2022
Primary completion
Apr 30, 2026
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- United TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Lung Biotechnology PBC
- First posted
- Jan 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
Conditions
- Pulmonary Arterial Hypertension
Interventions
Parenteral TreprostinilDrug
Parenteral treprostinil will be administered per schedule specified in the arm description.
Oral TreprostinilDrug
Oral treprostinil will be administered per schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Right Ventricular Ejection Fraction (RVEF), as Measured by Cardiac Magnetic Resonance Imaging (cMRI) at Month 12Time frame: Baseline, Month 12
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center (University of Arizona)
Phoenix, Arizona
HonorHealth John C. Lincoln Medical Center
Phoenix, Arizona
University of California San Francisco - Fresno
Fresno, California
Cedars-Sinai Medical Center
Los Angeles, California
University of California Davis Medical Center
Sacramento, California
University of California San Francisco Pulmonary, Critical Care, Allergy and Sleep Medicine
San Francisco, California
Hartford Hospital
Hartford, Connecticut
USF
Tampa, Florida
Georgia Clinical Research
Austell, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
Indiana University Health North Hospital
Indianapolis, Indiana
Community Health Network
Indianapolis, Indiana
Brigham and Women's Hospital
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
University of Nebraska Medical Center
Omaha, Nebraska
Morristown Medical Center
Morristown, New Jersey
University of Rochester Medical Center
Rochester, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
University of Cincinnati
Cincinnati, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
Integris Baptist Medical Center
Oklahoma City, Oklahoma
Oklahoma Heart Institute
Tulsa, Oklahoma
Temple Hospital
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Prisma Health
Greenville, South Carolina
UT Southwestern Medical Center
Dallas, Texas
Carilion Clinic
Roanoke, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.